A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia

Leukemia

Volumn 27, Issue 10, 2013, Pages 2023-2031

  Metzeler, K H ^a   Maharry, K ^a,b   Kohlschmidt, J ^a,b   Volinia, S ^a   Mrozek K ^a   Becker, H ^a   Nicolet, D ^a,b   Whitman, S P ^a   Mendler, J H ^a   Schwind, S ^a   Eisfeld, A K ^a   Wu, Y Z ^a   Powell, B L ^c   Carter, T H ^d   Wetzler, M ^e   Kolitz, J E ^f   Baer, M R ^g   Carroll, A J ^h   Stone, R M ⁱ   Caligiuri, M A ^a   Marcucci, G ^a   Bloomfield, C D ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF IOWA   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

^f DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^g UNIVERSITY OF MARYLAND   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

acute myeloid leukemia; gene expression profiling; gene mutations; leukemic stem cells; prognostication

Indexed keywords

BAALC PROTEIN; CEBPA PROTEIN; MICRORNA; MICRORNA 155; TET2 PROTEIN; TRANSCRIPTION FACTOR ERG; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STEM CELL; CELL FUNCTION; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICRORNAS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REMISSION INDUCTION; STEM CELLS; SURVIVAL RATE; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84885662838     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.181     Document Type: Article

References (45)

1. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
2. Lapidot T, Fajerman Y, Kollet O. Immune-deficient SCID and NOD/SCID mice models as functional assays for studying normal and malignant human hematopoiesis. J Mol Med (Berl) 1997; 75: 664-673.
3. Sarry J-E, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgc-deficient mice. J Clin Invest 2011; 121: 384-395.
4. Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J et al. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia 2012; 26: 858-860.
5. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093.
6. Mró zek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol 2008; 33: 239-244.
7. Whitman SP, Maharry K, Radmacher MD, Becker H, Mró zek K, Margeson D et al. FLT3 internal tandem duplication associates with adverse outcome and gene-and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 3622-3626.
8. Becker H, Marcucci G, Maharry K, Radmacher MD, Mró zek K, Margeson D et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 596-604.
9. Marcucci G, Maharry K, Radmacher MD, Mró zek K, Vukosavljevic T, Paschka P et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 5078-5087.
10. Becker H, Marcucci G, Maharry K, Radmacher MD, Mró zek K, Margeson D et al. Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 788-792.
11. Mendler JH, Maharry K, Radmacher MD, Mró zek K, Becker H, Metzeler KH et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol 2012; 30: 3109-3118.
12. Metzeler KH, Maharry K, Radmacher MD, Mró zek K, Margeson D, Becker H et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2011; 29: 1373-1381.
13. Marcucci G, Metzeler KH, Schwind S, Becker H, Maharry K, Mró zek K et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012; 30: 742-750.
14. Metzeler KH, Becker H, Maharry K, Radmacher MD, Kohlschmidt J, Mró zek K et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 2011; 118: 6920-6929.
15. Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mró zek K, Margeson D et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 2348-2355.
16. Whitman SP, Ruppert AS, Radmacher MD, Mró zek K, Paschka P, Langer C et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008; 111: 1552-1559.
17. Whitman SP, Caligiuri MA, Maharry K, Radmacher MD, Kohlschmidt J, Becker H et al. The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia 2012; 26: 1713-1717.
18. Caligiuri MA, Strout MP, Schichman SA, Mró zek K, Arthur DC, Herzig GP et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418-1425.
19. Schwind S, Marcucci G, Maharry K, Radmacher MD, Mró zek K, Holland KB et al. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 5660-5669.
20. Schwind S, Marcucci G, Kohlschmidt J, Radmacher MD, Mró zek K, Maharry K et al. Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia. Blood 2011; 118: 4188-4198.
21. Marcucci G, Maharry K, Metzeler KH, Volinia S, Wu Y-Z, Mró zek K et al. Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol 2013; 31: 2086-2093.
22. Döhner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
23. Mró zek K, Marcucci G, Nicolet D, Maharry KS, Becker H, Whitman SP et al. Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. J Clin Oncol 2012; 30: 4515-4523.
24. Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011; 29: 2758-2765.
25. Schwind S, Maharry K, Radmacher MD, Mró zek K, Holland KB, Margeson D et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2010; 28: 5257-5264.
26. Eisfeld A-K, Marcucci G, Maharry K, Schwind S, Radmacher MD, Nicolet D et al. miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 2012; 120: 249-258.
27. Gerrits A, Walasek MA, Olthof S, Weersing E, Ritsema M, Zwart E et al. Genetic screen identifies microRNA cluster 99b/let-7e/125a as a regulator of primitive hematopoietic cells. Blood 2012; 119: 377-387.
28. Shaham L, Binder V, Gefen N, Borkhardt A, Izraeli S. MiR-125 in normal and malignant hematopoiesis. Leukemia 2012; 26: 2011-2018.
29. Bousquet M, Harris MH, Zhou B, Lodish HF. MicroRNA miR-125b causes leukemia. Proc Natl Acad Sci USA 2010; 107: 21558-21563.
30. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk P, Lowenberg B. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008; 111: 5078-5085.
31. Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med 2010; 16: 49-58.
32. Starczynowski DT, Kuchenbauer F, Wegrzyn J, Rouhi A, Petriv O, Hansen CL et al. MicroRNA-146a disrupts hematopoietic differentiation and survival. Exp Hematol 2011; 39: 167-178.
33. Havelange N, Stauffer N, Heaphy CCE, Volinia S, Andreeff M, Marcucci G et al. Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer 2011; 117: 4696-4706.
34. Quinn EM, Wang JH, Redmond HP. The emerging role of microRNA in regulation of endotoxin tolerance. J Leukoc Biol 2012; 91: 721-727.
35. Häger M, Pedersen CC, Larsen MT, Andersen MK, Hother C, Gronbaek K et al. MicroRNA-130a-mediated down-regulation of Smad4 contributes to reduced sensitivity to TGF-b1 stimulation in granulocytic precursors. Blood 2011; 118: 6649-6659.
36. Guo S, Lu J, Schlager R, Zhang H, Wang JY, Fox MC et al. MicroRNA miR-125a controls hematopoietic stem cell number. Proc Natl Acad Sci USA 2010; 107: 14229-14234.
37. Rizzo M, Mariani L, Pitto L, Rainaldi G, Simili M. miR-20a and miR-290, multifaceted players with a role in tumourigenesis and senescence. J Cell Mol Med 2010; 14: 2633-2640.
38. Lu D, Davis MPA, Abreu-Goodger C, Wang W, Campos LS, Siede J et al. MiR-25 regulates Wwp2 and Fbxw7 and promotes reprogramming of mouse fibroblast cells to iPSCs. PLoS One 2012; 7: e40938.
39. Li Z, Lu J, Sun M, Mi S, Zhang H, Luo RT et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci USA 2008; 105: 15535-15540.
40. Li Y, Vecchiarelli-Federico LM, Li Y-J, Egan SE, Spaner D, Hough MR et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood 2012; 119: 4486-4498.
41. Garzon R, Volinia S, Liu C-G, Fernandez-Cymering C, Palumbo T, Pichiorri F et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008; 111: 3183-3189.
42. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA 2010; 304: 2706-2715.
43. Marcucci G, Mró zek K, Radmacher MD, Garzon R, Bloomfield CD. The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood 2011; 117: 1121-1129.
44. Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A et al. Lenalidomide-mediated enhanced translation of C/EBPa-p30 protein upregulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013; 121: 159-169.
45. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694.